
Quarterly report 2025-Q2
added 07-22-2025
IQVIA Holdings EPS Ratio 2011-2025 | IQV
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio IQVIA Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.57 | 7.39 | 5.82 | 5.05 | 1.46 | 0.98 | 1.27 | 5.86 | 0.48 | 3.15 | 2.78 | 1.83 | 1.53 | 2.08 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.57 | 0.48 | 3.38 |
Quarterly EPS Ratio IQVIA Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.55 | 1.42 | - | 1.57 | 1.99 | 1.58 | - | 1.66 | 1.61 | 1.56 | - | 1.52 | 1.36 | 1.71 | - | 1.36 | 0.91 | 1.11 | 0.62 | 0.53 | -0.12 | 0.43 | 0.09 | 0.29 | 0.31 | 0.29 | 0.34 | 0.3 | 0.3 | 0.33 | 4.91 | 0.41 | 0.28 | 0.43 | -0.74 | 0.83 | 0.73 | 0.89 | 0.86 | 0.91 | 0.69 | 0.69 | 0.7 | 0.73 | 0.66 | 0.69 | 0.57 | 0.52 | 0.31 | 0.42 | 0.3 | 0.45 | 0.41 | 0.37 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.91 | -0.74 | 0.833 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
1.4 | $ 64.79 | 2.0 % | $ 25 B | ||
|
Brainsway Ltd.
BWAY
|
-0.24 | $ 17.23 | 1.5 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 21.15 | 11.37 % | $ 233 M | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
-4.67 | $ 101.24 | 0.04 % | $ 18.8 B | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.31 | 2.01 % | $ 5.31 M | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.69 | -1.74 % | $ 2.15 M | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | $ 0.36 | -0.39 % | $ 10.6 M | ||
|
Guardant Health
GH
|
-3.56 | $ 104.81 | -0.39 % | $ 12.9 B | ||
|
Celcuity
CELC
|
-2.83 | $ 98.24 | -0.25 % | $ 3.88 B | ||
|
DarioHealth Corp.
DRIO
|
1.93 | $ 11.75 | -0.47 % | $ 333 M | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 185.09 | 2.99 % | $ 15.3 B | ||
|
IDEXX Laboratories
IDXX
|
10.8 | $ 733.11 | 0.57 % | $ 60.5 B | ||
|
Danaher Corporation
DHR
|
5.33 | $ 228.08 | 1.74 % | $ 167 B | ||
|
Illumina
ILMN
|
-7.69 | $ 128.88 | 0.12 % | $ 20.5 B | ||
|
Anixa Biosciences
ANIX
|
-0.39 | $ 4.25 | -3.41 % | $ 136 K | ||
|
Laboratory Corporation of America Holdings
LH
|
8.89 | $ 267.33 | -0.14 % | $ 22.4 B | ||
|
Lantheus Holdings
LNTH
|
4.52 | $ 58.6 | -0.81 % | $ 4.06 B | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Medpace Holdings
MEDP
|
13.1 | $ 589.45 | 0.25 % | $ 18.2 B | ||
|
Mettler-Toledo International
MTD
|
40.7 | $ 1 457.09 | -0.75 % | $ 30.9 B | ||
|
Myriad Genetics
MYGN
|
-1.41 | $ 7.06 | -0.03 % | $ 640 M | ||
|
ENDRA Life Sciences
NDRA
|
-5.55 | $ 5.81 | -1.43 % | $ 3.12 M | ||
|
NeoGenomics
NEO
|
-0.62 | $ 12.02 | -0.04 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 5.91 | -0.25 % | $ 1.28 B | ||
|
Biodesix
BDSX
|
-0.33 | $ 7.79 | - | $ 1.01 B | ||
|
National Research Corporation
NRC
|
1.26 | $ 16.27 | -3.1 % | $ 399 M | ||
|
Natera
NTRA
|
-5.57 | $ 237.72 | 1.48 % | $ 23.4 B | ||
|
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 39.24 | 0.31 % | $ 1.09 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.78 | $ 184.06 | 0.16 % | $ 20.4 B | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 28.38 | -0.49 % | $ 858 M | ||
|
Organovo Holdings
ONVO
|
-1.7 | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
2.44 | - | -16.95 % | $ 1.54 M | ||
|
Pacific Biosciences of California
PACB
|
-1.21 | $ 2.33 | 4.69 % | $ 591 M | ||
|
PerkinElmer
PKI
|
2.21 | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
-0.72 | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
-4.51 | $ 24.56 | 8.81 % | $ 31.9 M | ||
|
Personalis
PSNL
|
-1.37 | $ 10.09 | 4.18 % | $ 598 M | ||
|
RadNet
RDNT
|
0.04 | $ 79.11 | -1.13 % | $ 5.78 B | ||
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M |